Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma - Wikidata - thesis-toulmin - TriplyDB

Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma

Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma

http://www.wikidata.org/entity/Q28472150

about

Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice Effect of pazopanib on tumor microenvironment and liposome delivery Increased fibrosis and interstitial fluid pressure in two different types of syngeneic murine carcinoma grown in integrin β3-subunit deficient mice.High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes.High interstitial fluid pressure is associated with tumor-line specific vascular abnormalities in human melanoma xenografts.Peptide-based targeting of the platelet-derived growth factor receptor beta.Targeting the PDGF signaling pathway in tumor treatment Intratumoral drug delivery with nanoparticulate carriers.A pilot study of the effects of mild systemic heating on human head and neck tumour xenografts: Analysis of tumour perfusion, interstitial fluid pressure, hypoxia and efficacy of radiation therapy.Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma.Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509 Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments.Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205.AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR.Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors.Tumor vasculature: the Achilles' heel of cancer?Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology.Pericytes: a double-edged sword in cancer therapy.Republished: Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology.A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition.Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review.Fibromodulin deficiency reduces collagen structural network but not glycosaminoglycan content in a syngeneic model of colon carcinoma.A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer.Inhibition of integrin αVβ6 changes fibril thickness of stromal collagen in experimental carcinomas.

P2860

Q33393552-939C3AAA-04FE-43B5-9EED-F6A6E6232D6B Q34018204-ABB32889-9BF2-40D0-BB0C-498A75D49D49 Q34222093-3E843AAE-B745-4AF1-B801-78260733BFA9 Q34270696-D279BD67-F8D8-49B4-892D-D9309D979E98 Q34328523-D7A01F1D-E451-4F90-90AC-A952E0A824B2 Q34335171-B9D1C252-462A-4164-A69D-13E7DDC8BF62 Q34393461-1ED8F3C8-E469-4B8E-9E38-C298D7C3CFAC Q35091415-0616508F-D881-435D-A511-0FA48E072F0B Q36068704-0293F9E7-2679-4257-9F87-94B34F883215 Q36288883-EF47E89F-E344-4F15-BBFC-49CCE1C4BB4D Q36337646-7A807BD8-C3DD-4BD1-A5A3-A29FFEC1258D Q36903863-F38CA695-9EC5-4F33-BC33-8D49B6C91963 Q37182171-EC88B909-36B0-4B94-A539-E619EBDA7979 Q37296212-16615B2F-9787-4213-8792-42F0A16A94DF Q37607383-4505673E-1CDA-4467-A7D7-AB335AAD3800 Q38057420-D33D3CE2-C70D-4359-A293-0AC7058D7DA3 Q38241160-8A8B9FA8-0B27-46CE-8295-0265B95D28C7 Q38241791-BB78789F-FEA0-4D2E-81AA-2DDDA9348EE1 Q38481540-04AE6251-6565-4886-A9D8-BDECA0C25D1A Q38718622-BDEA7AD0-9030-4689-BF6A-5CD1B444E076 Q41258130-D06047A2-4406-47EC-B4BC-A7840CF11106 Q41475309-5DF3D2BE-E687-43A2-B0AD-6F1434A27AE4 Q45228150-74CDA3EB-E6A2-4A77-8CDC-8A1A7F944DC1 Q55475652-2A5A4627-EE9E-4E51-828D-D3576CCC30C3

P2860

Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma

http://www.wikidata.org/entity/Q28472150

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Combined anti-angiogenic thera ...... murine experimental carcinoma

@ast

Combined anti-angiogenic thera ...... murine experimental carcinoma

@en

Combined anti-angiogenic thera ...... murine experimental carcinoma

@nl

type

label

Combined anti-angiogenic thera ...... murine experimental carcinoma

@ast

Combined anti-angiogenic thera ...... murine experimental carcinoma

@en

Combined anti-angiogenic thera ...... murine experimental carcinoma

@nl

prefLabel

Combined anti-angiogenic thera ...... murine experimental carcinoma

@ast

Combined anti-angiogenic thera ...... murine experimental carcinoma

@en

Combined anti-angiogenic thera ...... murine experimental carcinoma

@nl

P1433

Q28472150-A40472C3-C8AD-48C8-B98F-C9991774F134

P1476

Q28472150-AC5049C8-996C-4D38-B7E8-3342557C2064

P2093

Q28472150-1A0DD6BB-3DFB-4381-9653-AEE038DA9184

Q28472150-3088AD10-E586-405E-A6CA-E538B2EE6401

Q28472150-77B2640A-E067-4E4E-BE21-B9F705D330D9

Q28472150-784BD34B-1F1A-491A-A78A-606BBC84CFAF

Q28472150-8F84177F-F69E-4E24-9B04-AC06DD4BBA6E

Q28472150-A9E7FA3B-981D-4ED9-B8AF-C9D09F2CF8FD

Q28472150-B759291C-0991-49D3-8CE5-BEFE5F344FE0

Q28472150-BB49E5E1-63DD-41D0-8CE8-4BB54FB9F5A0

Q28472150-CF4809B7-F7C2-44C6-9F41-B2FA998A0805

P2860

Q28472150-124CDFA7-61F1-437A-BAB9-EA5D8833B893

Q28472150-1B77169D-051E-4411-94D6-4C15447FB561

Q28472150-2565A13E-F15A-4F64-95C2-A717B2E94D8A

Q28472150-2F6F0A21-A40E-44B9-AE66-64AE5852C40A

Q28472150-3D0D95B3-7423-4CAA-9A07-74B018101D6F

Q28472150-516C0E23-7707-4C5F-B87D-DBA368DC7ABB

Q28472150-539699ED-1CA7-455B-8B5B-9AD83CB38F93

Q28472150-5F2E37A5-9480-419E-B682-A15C07235761

Q28472150-67CBD7D3-BFBB-4FB5-A7EA-8B1D57A4ECBB

Q28472150-9947BD37-9889-4659-8811-E5C357624EFF

P304

Q28472150-0E9BE639-5995-469D-BAD7-1A966538C583

P31

Q28472150-0EE5259D-8463-4473-9DBE-F71DD7FC29AA

P356

Q28472150-BC8E2B32-CDE5-4609-88D7-BC56CB10DA5C

P407

Q28472150-1E97B18E-6621-456E-A3BB-1D520835249B

P433

Q28472150-8198DE7F-45EB-4050-8D0F-E76240AEDE70

P478

Q28472150-8022A7B6-8223-4962-A8C1-F6D6DCD31749

P50

Q28472150-07CBE162-3A5C-4EAD-BCC3-90610BC0F031

P577

Q28472150-8359367D-8630-4F9D-B171-E99D99F4F087

P5875

Q28472150-BD49289B-6D73-4EDA-A5A9-D3F29056608B

P698

Q28472150-2AB5AAB6-3FEE-4896-8FD2-EE45497F74B3

P932

Q28472150-4F96523D-1DC0-4444-B612-C0445845978C

P356

JOURNAL.PONE.0008149

P1433

P1476

Combined anti-angiogenic thera ...... murine experimental carcinoma

@en

P2093

Agnieszka Kłosowska-Wardega

http://www.w3.org/2001/XMLSchema#string

Aive Ahgren

http://www.w3.org/2001/XMLSchema#string

Carina Hellberg

http://www.w3.org/2001/XMLSchema#string

Carl-Henrik Heldin

http://www.w3.org/2001/XMLSchema#string

Ingrid Moen

http://www.w3.org/2001/XMLSchema#string

Kristofer Rubin

http://www.w3.org/2001/XMLSchema#string

Linda Stuhr

http://www.w3.org/2001/XMLSchema#string

Mikhail Burmakin

http://www.w3.org/2001/XMLSchema#string

Yoko Hasumi

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action and in vivo role of platelet-derived growth factor

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

Molecular regulation of angiogenesis and lymphangiogenesis

High interstitial fluid pressure - an obstacle in cancer therapy

Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy.

Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma.

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.

Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors

Haemodynamic and transport barriers to the treatment of solid tumours.

Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

P304

e8149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0008149

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40484406

http://www.w3.org/2001/XMLSchema#string

P698

19997591

http://www.w3.org/2001/XMLSchema#string

P932

2781164

http://www.w3.org/2001/XMLSchema#string